Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hospira
Hospira
Activities:
Drug Delivery
Pharmaceutical
A global specialty pharmaceutical and medication delivery company.
X
LinkedIn
Trending Articles
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Adare expands global handling & packaging capabilities
The company will have enhanced compaction, milling, bin blending and tablet compression capabilities in Philadelphia, Ohio and Milan
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
FDA cautions Pfizer subsidiary in India in quality control warning letter
The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery
Mylan and Hospira voluntarily recall injectables
Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory
Brussels explains why it approved Pfizer/Hospira deal
Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory
Hospira calls for biosimilars to have same name as biologicals
Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development
Hospira and Pfenex link up to develop Lucentis biosimilar
Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery
Pfizer to acquire Hospira
Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing
Opinion: Still not getting it right
The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now